{{NoteTA
|1=zh-cn:障碍;zh-hk:障礙;zh-tw:疾患;
}}
{{醫學聲明}}{{expert|time=2017-04-15T04:29:23+00:00}}
{{Distinguish|體育禁藥}}
[[File:Ritalin-SR-20mg-full.jpg|thumb]]錠]]
[[File:Cocaine_lines_2.jpg|thumb]]常拿來做為娛樂性藥物]]

'''興奮劑'''又稱為'''中樞神經興奮劑'''、'''中樞神經刺激劑'''（{{lang-en|'''stimulant'''、'''psycho-stimulant'''}}）是一系列可刺激[[中樞神經系統|中樞神經系統]]和[[大腦|腦部]][[脊髓|脊髓]]的[[精神藥物|精神藥物]]統稱，其中包括可以增加活動力的藥物<ref>{{cite web|title=stimulant - definition of stimulant in English {{!}} Oxford Dictionaries|url=https://en.oxforddictionaries.com/definition/stimulant|website=Oxford Dictionaries {{!}} English|accessdate=2017-04-15|archive-date=2017-02-26|archive-url=https://web.archive.org/web/20170226074716/https://en.oxforddictionaries.com/definition/stimulant|dead-url=no}}</ref>、會令人感到愉快和振奮的藥物，以及有交感兴奋作用的藥物<ref>{{cite book|last1=Treatment|first1=Center for Substance Abuse|title=Chapter 2—How Stimulants Affect the Brain and Behavior|publisher=Substance Abuse and Mental Health Services Administration (US)|url=https://www.ncbi.nlm.nih.gov/books/NBK64328/|language=en|access-date=2017-04-15|archive-date=2017-02-19|archive-url=https://web.archive.org/web/20170219042946/https://www.ncbi.nlm.nih.gov/books/NBK64328/|dead-url=no}}</ref>。兴奋剂可以提升警覺心、[[注意力|注意力]]和活力，同時也增加[[血壓|血壓]]、[[心跳|心跳]]和[[呼吸|呼吸]]<ref name="NIMH on stimulant"/>，常用作[[處方藥|處方藥]]（例如[[ADHD|ADHD]]的兒童或成人<ref name="NIMH on stimulant">{{cite web
| url=https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml#part_149861
| website=National Institute of mental health.
| title=Mental Health Medications.
| date=October 2016
| access-date=2017-04-15
| type=tertiary source
| archive-date=2019-04-06
| archive-url=https://web.archive.org/web/20190406082433/https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml#part_149861
| dead-url=no
}}</ref>、[[嗜睡症|嗜睡症]]、[[食慾|抑制食慾]]），但也有用於藥物治療以外的使用（可能是{{le|脱法药物|Legal intoxicant}}或是[[毒品|非法使用]]），可能做為[[表現增強物質|表現增強物質]]或是[[娛樂性藥物|娛樂性藥物]]。

一些藥物能影響自我管理能力。例如：歸類為中樞神經興奮劑的藥物：[[哌甲酯|哌甲酯]]（methylphenidate）和[[安非他命|安非他命]]（amphetamine）。<u>適度適量</u>使用，能提升一個人整體的[[衝動控制能力|衝動控制能力]]（inhibitory control），且被用來治療[[注意力不足過動症|注意力不足過動症]]（ADHD）患者。<ref name="Unambiguous PFC D1 A2">{{cite journal | vauthors = Spencer RC, Devilbiss DM, Berridge CW | title = The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex | journal = Biol. Psychiatry | volume = 77 | issue = 11 | pages = 940–950 | year = June 2015 | pmid = 25499957 | doi = 10.1016/j.biopsych.2014.09.013 | quote = The procognitive actions of psychostimulants are only associated with low doses. Surprisingly, despite nearly 80 years of clinical use, the neurobiology of the procognitive actions of psychostimulants has only recently been systematically investigated. Findings from this research unambiguously demonstrate that the cognition-enhancing effects of psychostimulants involve the preferential elevation of catecholamines in the PFC and the subsequent activation of norepinephrine α2 and dopamine D1 receptors. ... This differential modulation of PFC-dependent processes across dose appears to be associated with the differential involvement of noradrenergic α2 versus α1 receptors. Collectively, this evidence indicates that at low, clinically relevant doses, psychostimulants are devoid of the behavioral and neurochemical actions that define this class of drugs and instead act largely as cognitive enhancers (improving PFC-dependent function). This information has potentially important clinical implications as well as relevance for public health policy regarding the widespread clinical use of psychostimulants and for the development of novel pharmacologic treatments for attention-deficit/hyperactivity disorder and other conditions associated with PFC dysregulation. ... In particular, in both animals and humans, lower doses maximally improve performance in tests of working memory and response inhibition, whereas maximal suppression of overt behavior and facilitation of attentional processes occurs at higher doses.}}</ref><ref name="Cognitive and motivational effects">{{cite journal | vauthors = Ilieva IP, Hook CJ, Farah MJ | title = Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis | journal = J. Cogn. Neurosci. | volume = | issue = | pages = 1–21 | date = January 2015 | pmid = 25591060 | doi = 10.1162/jocn_a_00776 | quote = Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities. ... The results of this meta-analysis ... do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size. }}</ref>
同理，{{tsl|en|depressants|中樞神經抑制劑}}（depressants）（例如：[[酒精|酒精]]）由於會讓腦中[[神經傳導物質|神經傳導物質]]濃度降低、減少許多大腦區域的活性等，所以可能會造成專注力、神智清醒度等自我管理能力的下降。<ref>{{cite web 
| url = http://www.drugfreeworld.org/drugfacts/prescription/depressants.html 
| title = Long-term & Short-term effects, depressants, brand names: Foundation for a drug free work 
| accessdate = 2017-04-30 
| archive-date = 2020-11-27 
| archive-url = https://web.archive.org/web/20201127014706/https://www.drugfreeworld.org/drugfacts/prescription/depressants.html 
| dead-url = no 
}}</ref>
<!-- Similarly, depressants, such as alcohol, represent barriers to self-control through sluggishness, slower brain function, poor concentration, depression and disorientation. -->

在美國，2013年最常用的處方藥兴奋剂有[[甲磺酸賴氨酸安非他命|甲磺酸賴氨酸安非他命]]、[[哌甲酯|哌甲酯]]及[[安非他命|安非他命]]<ref>{{cite web|title=Top 100 Drugs for Q4 2013 by Sales - U.S. Pharmaceutical Statistics|url=https://www.drugs.com/stats/top100/sales|website=www.drugs.com|accessdate=2017-04-15|archive-date=2013-08-14|archive-url=https://web.archive.org/web/20130814232045/http://www.drugs.com/stats/top100/sales|dead-url=no}}</ref>。

==作用機制==
大多數興奮劑通過增強[[兒茶酚胺|兒茶酚胺]][[神經傳遞|神經傳遞]]發揮其激活作用。兒茶酚胺[[神經遞質|神經遞質]]被用於涉及注意力、喚醒、動機、任務顯著性和報酬預期的調節途徑中。經典的興奮劑要麼[[單胺再攝取抑制劑|阻止再攝取]]，要麼[[單胺釋放劑|刺激這些兒茶酚胺的外排]]，導致其迴路活動增加。一些興奮劑，特別是那些具有致病和致幻作用的興奮劑，也會影響血清素能的傳遞。一些興奮劑，例如一些苯丙胺衍生物，尤其是[[育亨賓|育亨賓]]，可以通過拮抗調節性自體受體來減少[[負反饋|負反饋]]。<ref>{{cite journal|last1=Docherty|first1=J R|title=Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)|journal=British Journal of Pharmacology|date=7 January 2017|volume=154|issue=3|pages=606–622|doi=10.1038/bjp.2008.124|pmc=2439527|issn=0007-1188|pmid=18500382}}</ref>[[腎上腺素能激動劑|腎上腺素能激動劑]]（例如，[[麻黃鹼|麻黃鹼]]）通過直接結合併激活[[腎上腺素能受體|腎上腺素能受體]]而起作用，產生[[擬交感神經|擬交感神經]]作用

藥物還可以具有更多間接機制來激發激活作用。例如[[咖啡因|咖啡因]]是[[腺苷受體拮抗劑|腺苷受體拮抗劑]]，僅間接增加兒茶酚胺在大腦中的傳播。<ref>{{cite book|title=Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations.|publisher=National Academies Press (US)|location=Washington (DC)|url=https://www.ncbi.nlm.nih.gov/books/NBK223808/|language=en|archiveurl=https://web.archive.org/web/20171009140913/https://www.ncbi.nlm.nih.gov/books/NBK223808/|archivedate=2017-10-09|year=2001|access-date=2020-11-07|dead-url=no}}</ref>而Pitolisant是H3受體反向激動劑。 由於H3受體主要充當自體受體，因此pitolisant減少了對組織胺能神經元的負反饋，從而增強了組織胺能傳遞。

==常見的興奮劑==

===安非他命===
{{Main|安非他命}}

[[安非他命|安非他命]]是[[苯乙胺|苯乙胺]]類的強力[[中樞神經系統|中樞神經系統]]（CNS）興奮劑，已被批准用於治療[[注意力不足過動症|注意力不足過動症]]（ADHD）和[[發作性嗜睡病|發作性嗜睡病]]。<ref name="FDA Abuse & OD">{{cite web |title=Adderall XR Prescribing Information |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf |page=11 |work=United States Food and Drug Administration |date=June 2013 |accessdate=7 January 2014 |archiveurl=https://web.archive.org/web/20141006101218/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf |archivedate=2014-10-06 |dead-url=no }}</ref>安非他命也可以作為[[表現增強物質|表現增強物質]]和[[聰明藥|認知增強劑]]使用，也可以作為[[春藥|春藥]]和[[娛樂性用藥|娛樂用]]的[[欣快感|欣快劑]]使用。<ref name="Ergogenics" /><ref name="Malenka_2009">{{cite book|vauthors=Malenka RC, Nestler EJ, Hyman SE |veditors=Sydor A, Brown RY |title=Molecular Neuropharmacology: A Foundation for Clinical Neuroscience |year=2009 |publisher=McGraw-Hill Medical |location=New York |isbn=978-0-07-148127-4 |page=318 |edition=2nd |chapter=Chapter 13: Higher Cognitive Function and Behavioral Control |quote=Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in individuals with ADHD and in normal subjects...it is now believed that dopamine and norepinephrine, but not serotonin, produce the beneficial effects of stimulants on working memory. At abused (relatively high) doses, stimulants can interfere with working memory and cognitive control, as will be discussed below. It is important to recognize, however, that stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks...through indirect stimulation of dopamine and norepinephrine receptors.}}</ref><ref name="Libido">{{cite journal|author=Montgomery KA |title=Sexual desire disorders |journal=Psychiatry |volume=5 |issue=6 |pages=50–55 |date=June 2008 |pmid=19727285 |pmc=2695750 |doi=}}</ref><ref name="Nonmedical">{{cite journal|vauthors=Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S |title=Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature |journal=J. Am. Acad. Child Adolesc. Psychiatry |volume=47 |issue=1 |pages=21–31 |date=January 2008 |pmid=18174822 |doi=10.1097/chi.0b013e31815a56f1 |quote=Stimulant misuse appears to occur both for performance enhancement and their euphorogenic effects, the latter being related to the intrinsic properties of the stimulants (e.g., IR versus ER profile)...<br /><br />Although useful in the treatment of ADHD, stimulants are controlled II substances with a history of preclinical and human studies showing potential abuse liability.}}</ref>儘管在許多國家或地區，安非他命是[[處方藥|處方藥]]，但未經控製或大量使用會帶來嚴重的健康風險，因此經常嚴格控制安非他命的未經授權擁有和分發。<ref name="UN Convention">{{cite web |title=Convention on psychotropic substances |url=http://treaties.un.org/Pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-16&chapter=6&lang=en |work=United Nations Treaty Collection |publisher=United Nations |accessdate=7 January 2014 |archiveurl=https://web.archive.org/web/20160331074842/https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-16&chapter=6&lang=en |archivedate=2016-03-31 |dead-url=no }}</ref><ref name="drugpolicy">{{cite web |title=Methamphetamine facts |url=http://www.drugpolicy.org/drug-facts/methamphetamine-facts |work=DrugPolicy.org |accessdate=7 January 2014 |archiveurl=https://web.archive.org/web/20180417185214/https://www.drugpolicy.org/drug-facts/methamphetamine-facts |archivedate=2018-04-17 |dead-url=no }}</ref>因此，許多安非他命是在[[秘密化學|秘密實驗室]]非法製造的，並被販運並出售給使用者。<ref name="World Drug Report" />根據全世界毒品的緝獲情況，安非他命的非法生產和販運比[[甲基安非他命|甲基安非他命]]要少得多。<ref name="World Drug Report">{{cite web |vauthors=Chawla S, Le Pichon T |title=World Drug Report 2006 |year=2006 |pages=128–135 |work=United Nations Office on Drugs and Crime |url=http://www.unodc.org/pdf/WDR_2006/wdr2006_volume1.pdf |accessdate=7 January 2014 |archiveurl=https://web.archive.org/web/20130530231143/http://www.unodc.org/pdf/WDR_2006/wdr2006_volume1.pdf |archivedate=2013-05-30 |dead-url=no }}</ref>

第一種藥物安非他命是Benzedrine，這是一種用於治療各種疾病的吸入器品牌。<ref name="Amph Uses">{{cite journal|vauthors=Heal DJ, Smith SL, Gosden J, Nutt DJ|date=June 2013|title=Amphetamine, past and present – a pharmacological and clinical perspective|journal=J. Psychopharmacol.|volume=27|issue=6|pages=479–496|doi=10.1177/0269881113482532|pmc=3666194|pmid=23539642}}</ref><ref name="Benzedrine">{{cite journal|author=Rasmussen N |title=Making the first anti-depressant: amphetamine in American medicine, 1929–1950 |url=https://archive.org/details/sim_journal-of-the-history-of-medicine-and-allied-sciences_2006-07_61_3/page/288 |journal=J. Hist. Med. Allied Sci. |volume=61 |issue=3 |pages=288–323 |date=July 2006 |pmid=16492800 |doi=10.1093/jhmas/jrj039}}</ref>由於右旋異構體具有更大的刺激性，因此逐漸停用Benzedrine，轉而使用含有全部或大部分右旋苯丙胺的製劑。目前，通常將其處方為[[阿得拉尔|混合的苯丙胺鹽]]、[[右旋苯丙胺|右旋苯丙胺]]和[[甲磺酸赖氨酸安非他命|甲磺酸赖氨酸安非他命]]。<ref name="Amph Uses" /><ref name="Adderall IR">{{cite web |title=Adderall IR Prescribing Information |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf |work=United States Food and Drug Administration |date=March 2007 |accessdate=2 November 2013 |page=5 |archiveurl=https://web.archive.org/web/20130926063018/http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf |archivedate=2013-09-26 |dead-url=no }}</ref>

苯丙胺是[[去甲基腎上腺素—多巴胺釋放劑|去甲基腎上腺素—多巴胺釋放劑]]（NDRA）。它通過[[多巴胺轉運體|多巴胺轉運體]]和[[去甲腎上腺素轉運體|去甲腎上腺素轉運體]]進入[[神經元|神經元]]，並通過激活[[TAAR1|TAAR1]]和抑制[[VMAT2|VMAT2]]促進[[神經遞質|神經遞質]]排出。<ref name="Miller">{{cite journal|author=Miller GM |title=The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity |journal=J. Neurochem. |volume=116 |issue=2 |pages=164–176 |date=January 2011 |pmid=21073468 |pmc=3005101 |doi=10.1111/j.1471-4159.2010.07109.x}}</ref>在治療劑量下，這會引起情緒和認知影響，例如[[欣快感|欣快感]]、[[性慾|性慾]]改變、[[喚起|喚起]]感增強和改善[[管控功能|認知控制]]。<ref name="Malenka_2009" /><ref name="Libido" /><ref name="FDA Effects">{{cite web |title=Adderall XR Prescribing Information |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf |pages=4–8 |work=United States Food and Drug Administration |date=June 2013 |accessdate=7 October 2013 |archiveurl=https://web.archive.org/web/20141006101218/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf |archivedate=2014-10-06 |dead-url=no }}</ref>同樣，它會誘發身體反應，例如減少反應時間、降低疲勞強度和增加肌肉強度。<ref name="Ergogenics">{{cite journal|vauthors=Liddle DG, Connor DJ |title=Nutritional supplements and ergogenic AIDS |journal=Prim. Care |volume=40 |issue=2 |pages=487–505 |date=June 2013 |pmid=23668655 |doi=10.1016/j.pop.2013.02.009 |quote=Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training...<br />Physiologic and performance effects<br />{{bull}}Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation<br />{{bull}}Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40<br />{{bull}}Improved reaction time<br />{{bull}}Increased muscle strength and delayed muscle fatigue<br />{{bull}}Increased acceleration<br />{{bull}}Increased alertness and attention to task}}</ref>相比之下，超過治療劑量的安非他命可能會損害[[認知功能|認知功能]]並引起[[橫紋肌溶解|橫紋肌溶解]]。<ref name="FDA Abuse & OD" /><ref name="Malenka_2009" /><ref name="Westfall">{{cite book |veditors=Brunton LL, Chabner BA, Knollmann BC |title=Goodman & Gilman's Pharmacological Basis of Therapeutics |year=2010 |publisher=McGraw-Hill |location=New York |isbn=978-0-07-162442-8 |vauthors=Westfall DP, Westfall TC |section=Miscellaneous Sympathomimetic Agonists |sectionurl=http://www.accessmedicine.com/content.aspx?aID=16661601 |edition=12th |access-date=2020-11-05 |archive-date=2013-11-10 |archive-url=https://web.archive.org/web/20131110094145/http://www.accessmedicine.com/content.aspx?aID=16661601 |dead-url=no }}</ref>超高劑量會導致[[精神病|精神病]]（例如[[妄想|妄想]]和[[偏執狂|偏執狂]]），即使長期使用治療劑量，這種情況也很少發生。<ref name="FDA Abuse & OD" /><ref name="Westfall" /><ref name="Cochrane">{{cite journal|vauthors=Shoptaw SJ, Kao U, Ling W |title=Treatment for amphetamine psychosis (Review) |journal=Cochrane Database of Systematic Reviews |year=2009 |issue=1|doi=10.1002/14651858.CD003026.pub3 |pmid=19160215 |pmc=7004251 |pages=CD003026}}</ref>由於娛樂劑量通常比規定的治療劑量大得多，因此娛樂性使用會產生嚴重的[[副作用|副作用]]（例如[[依賴性|依賴性]]）的風險要大得多，苯丙胺類藥物的治療很少會出現這種副作用。<ref name="FDA Abuse & OD" /><ref name="Westfall" /><ref name="Cochrane" />

=== 咖啡因 ===
{{Main|咖啡因}}
[[File:Roasted_coffee_beans.jpg|180px]]

[[咖啡因|咖啡因]]是一種興奮性化合物，屬於[[黃嘌呤|黃嘌呤]]類化學物質，天然存在於[[咖啡|咖啡]]、[[茶|茶]]和（較小程度上）[[可可|可可]]或[[巧克力|巧克力]]中。它包含在許多[[軟性飲料|軟性飲料]]中，以及大量的[[能量飲料|能量飲料]]中。咖啡因是世界上使用最廣泛的精神活性藥物，也是迄今為止最常見的興奮劑。在北美，每天有90％的成年人食用咖啡因。<ref name="demon drink">{{cite journal |author=Lovett R |title=Coffee: The demon drink? |journal=New Scientist |issue=2518 |date=24 September 2005 |url=https://www.newscientist.com/article.ns?id=mg18725181.700 |accessdate=3 August 2009 |archiveurl=https://web.archive.org/web/20081011095505/http://www.newscientist.com/article.ns?id=mg18725181.700 |archivedate=2008-10-11 |dead-url=no }}{{subscription required}}</ref>一些司法管轄區限制其銷售和使用。咖啡因也包括在某些藥物中，通常是為了增強主要成分的作用或減少其某項副作用（尤其是嗜睡）。含有標準劑量咖啡因的片劑也可以廣泛獲得。

咖啡因的作用機制不同於許多興奮劑，因為它通過抑制[[腺苷受體|腺苷受體]]產生興奮作用。<ref>{{cite journal|last1=Nehlig|first1=A.|last2=Daval|first2=J. L.|last3=Debry|first3=G.|title=Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects|journal=Brain Research. Brain Research Reviews|date=1 August 2016|volume=17|issue=2|pages=139–170|pmid=1356551|doi=10.1016/0165-0173(92)90012-b}}</ref>腺苷受體被認為是嗜睡和睡眠的主要驅動力，其作用隨著清醒時間的延長而增強。<ref>{{cite journal|last1=Bjorness|first1=Theresa E|last2=Greene|first2=Robert W|title=Adenosine and Sleep|journal=Current Neuropharmacology|date=8 January 2017|volume=7|issue=3|pages=238–245|doi=10.2174/157015909789152182|pmc=2769007|issn=1570-159X|pmid=20190965}}</ref>在動物模型中發現咖啡因可增加紋狀體多巴胺，<ref>{{cite journal|last1=Solinas|first1=Marcello|last2=Ferré|first2=Sergi|last3=You|first3=Zhi-Bing|last4=Karcz-Kubicha|first4=Marzena|last5=Popoli|first5=Patrizia|last6=Goldberg|first6=Steven R.|title=Caffeine Induces Dopamine and Glutamate Release in the Shell of the Nucleus Accumbens|url=https://archive.org/details/sim_journal-of-neuroscience_2002-08-01_22_15/page/n32|journal=Journal of Neuroscience|date=1 August 2002|volume=22|issue=15|pages=6321–6324|language=en|issn=0270-6474|doi=10.1523/JNEUROSCI.22-15-06321.2002|pmid=12151508|pmc=6758129}}</ref>並抑制[[腺苷受體|腺苷受體]]對[[多巴胺受體|多巴胺受體]]的抑制作用，<ref name="pmid12804599">{{cite journal | vauthors = Kamiya T, Saitoh O, Yoshioka K, Nakata H | title = Oligomerization of adenosine A2A and dopamine D2 receptors in living cells | journal = Biochemical and Biophysical Research Communications | volume = 306 | issue = 2 | pages = 544–9  | date = Jun 2003 | pmid = 12804599 | doi = 10.1016/S0006-291X(03)00991-4 }}</ref>然而，對人體的影響尚不清楚。與大多數興奮劑不同，咖啡因沒有[[成癮性|成癮性]]。咖啡因似乎不是增強刺激，實際上可能會發生某種程度的厭惡，在NIDA研究專著中發表的一項關於藥物濫用責任的研究中，人們更喜歡安慰劑而不是咖啡因。<ref>{{cite book|last1=Fishchman|first1=N|last2=Mello|first2=N|title=Testing for Abuse Liability of Drugs in Humans|publisher=U.S. Department of Health and Human Services Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse|location=5600 Fishers Lane Rockville, MD 20857|page=179|url=http://ww1.drugabuse.gov/pdf/monographs/92.pdf|url-status=dead|archiveurl=https://web.archive.org/web/20161222041641/http://ww1.drugabuse.gov/pdf/monographs/92.pdf|archivedate=2016-12-22|access-date=2020-11-05}}</ref>在大型電話調查中，只有11％的人報告了依賴症狀。然而，當人們在實驗室接受測試時，只有一半聲稱擁有依賴性的人實際經歷過這種情況，這對咖啡因產生依賴性的能力產生了懷疑，並使社會壓力成為人們關注的焦點。<ref name="pmid19428492">{{cite journal | vauthors = Temple JL | title = Caffeine use in children: what we know, what we have left to learn, and why we should worry | journal = Neuroscience and Biobehavioral Reviews | volume = 33 | issue = 6 | pages = 793–806 | year = 2009 | pmid = 19428492 | pmc = 2699625 | doi = 10.1016/j.neubiorev.2009.01.001 }}</ref>

飲用咖啡與降低[[癌症|癌症]]的總體風險有關。<ref name="pmid18834663">{{cite journal | author = Nkondjock A | title = Coffee consumption and the risk of cancer: an overview | journal = Cancer Lett. | volume = 277 | issue = 2 | pages = 121–5 | date = May 2009 | pmid = 18834663 | doi = 10.1016/j.canlet.2008.08.022 }}</ref>這主要是由於降低了[[肝細胞癌|肝細胞癌]]和[[子宮內膜癌|子宮內膜癌]]的風險，但對[[大腸癌|大腸癌]]的影響也可能較小。<ref name=Cancer10/>對於其他類型的癌症似乎沒有顯著的保護作用，而大量喝咖啡可能會增加患[[膀胱癌|膀胱癌]]的風險。<ref name=Cancer10>{{cite journal | author = Arab L | title = Epidemiologic evidence on coffee and cancer | journal = Nutrition and Cancer | volume = 62 | issue = 3 | pages = 271–83 | year = 2010 | pmid = 20358464 | doi = 10.1080/01635580903407122 }}</ref>咖啡因可能對[[阿茲海默症|阿茲海默症]]有保護作用，但證據尚無定論。<ref name="pmid20182026">{{cite journal |vauthors=Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N | title = Caffeine intake and dementia: systematic review and meta-analysis | journal = J. Alzheimers Dis. | volume = 20 Suppl 1 | pages = S187–204 | year = 2010 | pmid = 20182026 | doi = 10.3233/JAD-2010-091387 }}</ref><ref name="pmid21427489">{{cite journal |vauthors=Marques S, Batalha VL, Lopes LV, Outeiro TF | title = Modulating Alzheimer's disease through caffeine: a putative link to epigenetics | journal = J. Alzheimers Dis. | volume = 24 | issue = 2 | pages = 161–71 | year = 2011 | pmid = 21427489 | doi = 10.3233/JAD-2011-110032 }}</ref><ref name="pmid20182037">{{cite journal | vauthors = Arendash GW, Cao C | title = Caffeine and coffee as therapeutics against Alzheimer's disease | journal = J. Alzheimers Dis. | volume = 20 Suppl 1 | issue =  | pages = S117–26 | year = 2010 | pmid = 20182037 | doi = 10.3233/JAD-2010-091249 | url = http://content.iospress.com/download/journal-of-alzheimers-disease/jad091249?id=journal-of-alzheimers-disease%2Fjad091249 | access-date = 2020-11-05 | archive-date = 2020-10-30 | archive-url = https://web.archive.org/web/20201030043012/https://content.iospress.com/download/journal-of-alzheimers-disease/jad091249?id=journal-of-alzheimers-disease%2Fjad091249 | dead-url = no }}</ref>適量喝咖啡可以降低罹患[[心血管疾病|心血管疾病]]的風險，<ref name=Ding2014>{{cite journal |vauthors=Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB | title = Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. | journal = Circulation | volume = 129 | issue = 6 | pages = 643–59 | date = 11 February 2014 | pmid = 24201300 | pmc = 3945962 | doi = 10.1161/circulationaha.113.005925 }}</ref>並且可以在某種程度上降低[[第2型糖尿病|第2型糖尿病]]的風險。<ref name=Dam08>{{cite journal | author = van Dam RM | title = Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer | journal = Applied Physiology, Nutrition, and Metabolism | volume = 33 | issue = 6 | pages = 1269–1283 | year = 2008 | pmid = 19088789 | doi = 10.1139/H08-120 }}</ref>與少喝或不喝咖啡相比，每天喝1-3杯咖啡不會影響患[[高血壓|高血壓]]的風險。但是，那些每天喝2至4杯的人的患病風險可能會略有增加。<ref name="pmid21450934">{{cite journal |vauthors=Zhang Z, Hu G, Caballero B, Appel L, Chen L | title = Habitual coffee consumption and risk of hypertension: a systematic review and meta-analysis of prospective observational studies |url=https://archive.org/details/sim_american-journal-of-clinical-nutrition_2011-06_93_6/page/1212 | journal = Am. J. Clin. Nutr. | volume = 93 | issue = 6 | pages = 1212–9 | date = June 2011 | pmid = 21450934 | doi = 10.3945/ajcn.110.004044 }}</ref>咖啡因可增加[[青光眼|青光眼]]患者的眼壓，但似乎不影響正常人。<ref name="pmid20706731">{{cite journal |vauthors=Li M, Wang M, Guo W, Wang J, Sun X | title = The effect of caffeine on intraocular pressure: a systematic review and meta-analysis | journal = Graefes Arch. Clin. Exp. Ophthalmol. | volume = 249 | issue = 3 | pages = 435–42 | date = March 2011 | pmid = 20706731 | doi = 10.1007/s00417-010-1455-1 }}</ref>它可以保護人們免於[[肝硬化|肝硬化]]。<ref name="pmid19825397">{{cite journal |vauthors=Muriel P, Arauz J | title = Coffee and liver diseases | journal = Fitoterapia | volume = 81 | issue = 5 | pages = 297–305 | year = 2010 | pmid = 19825397 | doi = 10.1016/j.fitote.2009.10.003 }}</ref>沒有證據表明咖啡會阻礙孩子的成長。<ref>{{cite book |author=O'Connor A |title=Never shower in a thunderstorm : surprising facts and misleading myths about our health and the world we live in |year=2007 |publisher=Times Books |location=New York |isbn=978-0-8050-8312-5 |page=144 |edition=1st |url=https://books.google.com/books?id=neuEbVUZik0C&pg=PA144 |accessdate=15 January 2014 |archive-date=2020-02-12 |archive-url=https://web.archive.org/web/20200212162921/https://books.google.com/books?id=neuEbVUZik0C&pg=PA144 |dead-url=no }}</ref>咖啡因可能會提高某些藥物的功效，包括用於治療[[頭痛|頭痛]]的藥物。<ref name="pmid21302868">{{cite journal |vauthors=Gilmore B, Michael M | title = Treatment of acute migraine headache | journal = Am Fam Physician | volume = 83 | issue = 3 | pages = 271–80 | date = February 2011 | pmid = 21302868 | doi =  }}</ref>如果在登高海拔的山區幾個小時前服用咖啡因，可能會減輕[[急性高山症|急性高山症]]的嚴重程度。<ref name="pmid20367483">{{cite journal | author = Hackett PH | title = Caffeine at high altitude: java at base Camp | journal = High Alt. Med. Biol. | volume = 11 | issue = 1 | pages = 13–7 | year = 2010 | pmid = 20367483 | doi = 10.1089/ham.2009.1077 }}</ref>

===麻黃鹼===
{{Main|麻黃鹼}}
[[麻黃鹼|麻黃鹼]]是一種[[擬交感神經|擬交感神經]][[胺|胺]]，其分子結構與眾所周知的藥物[[苯丙醇胺|苯丙醇胺]]和[[甲基苯丙胺|甲基苯丙胺]]，以及重要的[[神經遞質|神經遞質]][[腎上腺素|腎上腺素]]相似。麻黃鹼通常用作興奮劑、食慾抑制劑、濃縮助劑和減充血藥，並用於治療與麻醉有關的[[低血壓|低血壓]]。

從化學意義上講，它是一種在[[麻黃屬|麻黃屬]]（[[麻黃科|麻黃科]]）的各種植物中發現的具有[[苯乙胺|苯乙胺]]骨架的[[生物鹼|生物鹼]]。其作用主要是通過增加[[去甲腎上腺素|去甲腎上腺素]]對[[腎上腺素能受體|腎上腺素能受體]]的活性。<ref name=merck>[http://www.merckmanuals.com/professional/lexicomp/ephedrine.html Merck Manuals EPHEDrine] {{Wayback|url=http://www.merckmanuals.com/professional/lexicomp/ephedrine.html |date=20110324031411 }} Last full review/revision January 2010</ref>它最通常以[[鹽酸鹽|鹽酸鹽]]或[[硫酸鹽|硫酸鹽]]的形式出售。

[[中藥|中藥]]中使用的[[草藥|草藥]][[麻黃|麻黃]]（Ephedra sinica）含有麻黃鹼和[[偽麻黃鹼|偽麻黃鹼]]作為其主要活性成分。含有其他麻黃種類提取物的其他草藥產品也可能如此。

===MDMA===
[[File:Ecstasy_monogram.jpg|thumb]]
{{Main|MDMA}}

3,4-亞甲二氧基甲基苯丙胺（MDMA, ecstasy,molly）是一種[[安非他命|安非他命]]類的[[欣快感|欣快劑]]、[[神入感激發劑|神入感激發劑]]和興奮劑。<ref>{{cite journal|last1=Meyer|first1=Jerrold S|title=3,4-methylenedioxymethamphetamine (MDMA): current perspectives|journal=Substance Abuse and Rehabilitation|date=21 November 2013|volume=4|pages=83–99|doi=10.2147/SAR.S37258|pmc=3931692|issn=1179-8467|pmid=24648791}}</ref>一些[[心理治療師|心理治療師]]短暫地將其用作治療的輔助手段，該藥物在[[娛樂性用藥|娛樂]]中大受歡迎，[[美國緝毒局|美國緝毒局]]將MDMA列為附表I受控物質，禁止大多數醫學研究和應用。MDMA以其神入感激發作用特性而聞名。MDMA的刺激作用包括[[高血壓|高血壓]]，[[食慾不振|食慾不振]]，[[欣快感|欣快感]]，[[社交抑制|社交抑制]]，[[失眠|失眠]]（增強清醒/無法入睡），能量改善，喚起感增強和排汗增加等。相對於[[兒茶酚胺能|兒茶酚胺能]]傳遞，與經典的興奮劑（如安非他命）相比，MDMA顯著增強了[[血清素能|血清素能]]傳遞。MDMA似乎沒有明顯的成癮或依賴性形成。<ref>{{cite journal|last1=Nutt|first1=David|last2=King|first2=Leslie A.|last3=Saulsbury|first3=William|last4=Blakemore|first4=Colin|title=Development of a rational scale to assess the harm of drugs of potential misuse|journal=Lancet |date=24 March 2007|volume=369|issue=9566|pages=1047–1053|doi=10.1016/S0140-6736(07)60464-4|pmid=17382831|issn=1474-547X}}</ref>

由於MDMA的相對安全性，一些研究人員（例如David Nutt）批評了調度水平，撰寫了一篇諷刺性的文章，發現MDMA的危險性比馬術低28倍，他稱這種情況為“馬術”或“馬匹成癮綜合症”。<ref>{{Cite news|title = Ecstasy 'no more dangerous than horse riding'|url = https://www.telegraph.co.uk/news/uknews/law-and-order/4537874/Ecstasy-no-more-dangerous-than-horse-riding.html|website = Telegraph.co.uk|accessdate = 4 December 2015|archiveurl = https://web.archive.org/web/20151210201615/http://www.telegraph.co.uk/news/uknews/law-and-order/4537874/Ecstasy-no-more-dangerous-than-horse-riding.html|archivedate = 2015-12-10|date = 2009-02-07|last1 = Editor|first1 = Christopher Hope|dead-url = no}}</ref>

===MDPV===
{{Main|MDPV}}

[[亞甲基二氧吡咯戊酮|亞甲基二氧吡咯戊酮]]（MDPV）是一種興奮性[[精神藥物|精神藥物]]，具有刺激性，可作為[[去甲腎上腺素-多巴胺再攝取抑制劑|去甲腎上腺素-多巴胺再攝取抑制劑]]（NDRI）。<ref name="SimmlerBuser2012">{{cite journal|last1=Simmler |first1=L. D. |last2=Buser |first2=T. A. |last3=Donzelli |first3=M. |last4=Schramm |first4=Y |last5=Dieu |first5=L-H. |last6=Huwyler |first6=J. |last7=Chaboz |first7=S. |last8=Hoener |first8=M. C. |last9=Liechti |first9=M. E. |title=Pharmacological characterization of designer cathinones in vitro |journal=[[British_Journal_of_Pharmacology|British Journal of Pharmacology]] |year=2012 |pages=458–470 |issn=0007-1188 |doi=10.1111/j.1476-5381.2012.02145.x |volume=168 |issue=2 |pmid=22897747 |pmc=3572571}}</ref>它是由勃林格殷格翰公司的一個團隊於1960年代首次開發的。<ref>US Patent 3478050 – 1-(3,4-methylenedioxy-phenyl)-2-pyrrolidino-alkanones</ref>直到2004年左右，MDPV仍然是一種無名的刺激劑，當時有報導稱它是作為設計藥物出售的。標有含MDPV的[[浴鹽|浴鹽]]的產品以前曾在美國的加油站和便利店以[[娛樂性用藥|娛樂性用藥]]的形式出售，類似於[[合成大麻素|Spice]]和[[合成大麻素|K2]]的營銷。<ref>{{cite journal |url=http://www.kmbc.com/news/26256067/detail.html |title=Abuse Of Fake 'Bath Salts' Sends Dozens To ER |date=23 December 2010 |publisher=KMBC.com |url-status=dead |archiveurl=https://web.archive.org/web/20110713161635/http://www.kmbc.com/news/26256067/detail.html |archivedate=2011-07-13 |journal= |access-date=2020-11-06 }}</ref><ref>{{cite web |url=http://healthybodydaily.com/dr-oz-in-case-you-missed-it/dr-oz-bath-salts-mdpv-bath-salts-drug-over-the-counter |title=MDPV Bath Salts Drug Over The Counter |url-status=dead |archiveurl=https://web.archive.org/web/20110310193146/http://healthybodydaily.com/dr-oz-in-case-you-missed-it/dr-oz-bath-salts-mdpv-bath-salts-drug-over-the-counter |archivedate=2011-03-10 |accessdate=2020-11-06 }}</ref>

心理和身體傷害事件均歸因於使用MDPV。<ref>{{cite news |accessdate=16 May 2011 |url=http://www.nbc33tv.com/consumer-alert/parents-cautioned-against-over-the-counter-synthetic-speed |title=Parents cautioned against over the counter synthetic speed |date=9 November 2010 |publisher=NBC 33 News |author=Samantha Morgan |archiveurl=https://web.archive.org/web/20110928084237/http://www.nbc33tv.com/consumer-alert/parents-cautioned-against-over-the-counter-synthetic-speed |archivedate=2011-09-28 |dead-url=no }}</ref><ref>{{cite news |accessdate=16 May 2011 |url=http://www.nbc33tv.com/news/bath-salts-used-to-get-high |title=Bath Salts Used to Get High |date=6 January 2011 |publisher=NBC 33 News |author=Kelsey Scram |archiveurl=https://web.archive.org/web/20110928084244/http://www.nbc33tv.com/news/bath-salts-used-to-get-high |archivedate=2011-09-28 |dead-url=no }}</ref>

===甲氧麻黃酮===
{{Main|甲氧麻黃酮}}

[[甲氧麻黃酮|甲氧麻黃酮]]是[[苯丙胺|苯丙胺]]和[[卡西酮|卡西酮]]類的合成興奮劑。俗名包括drone<ref name=Cumming>{{cite news |last=Cumming |first=E. |url=https://www.telegraph.co.uk/health/7614099/Mephedrone-Chemistry-lessons.html |title=Mephedrone: Chemistry lessons |newspaper=The Daily Telegraph |date=22 April 2010 |accessdate=14 September 2010 |location=London |archiveurl=https://web.archive.org/web/20140107033621/http://news.bbc.co.uk/2/hi/uk_news/scotland/north_east/8555872.stm |archivedate=2014-01-07 |dead-url=no }}</ref>和MCAT。<ref name=bbc0803>{{cite news |url=http://news.bbc.co.uk/1/hi/scotland/north_east/8555872.stm |title=Drugs crackdown hailed a success |work=BBC News |date=8 March 2010 |accessdate=31 March 2010 |archiveurl=https://web.archive.org/web/20120826231758/http://www.telegraph.co.uk/health/7614099/Mephedrone-Chemistry-lessons.html |archivedate=2012-08-26 |dead-url=no }}</ref>據報導，它是在中國製造的，化學上類似於在[[東非|東非]][[巧茶|卡塔]]植物中發現的卡西酮化合物。它以片劑或粉劑形式出現，使用者可以吞嚥、鼻腔吸入或注射，產生與[[搖頭丸|搖頭丸]]、[[苯丙胺|苯丙胺]]和[[可卡因|可卡因]]相似的作用。

甲氧麻黃酮於1929年首次合成，但直到2003年重新發現後才廣為人知。據報告，到2007年，甲氧麻黃酮可在[[互聯網|互聯網]]上出售； 到2008年，執法機構已意識到該化合物； 到2010年，在[[歐洲|歐洲]]大部分地區都有報導，在[[英國|英國]]尤為普遍。甲氧麻黃酮在2008年首先在[[以色列|以色列]]被定為非法，隨後是[[瑞典|瑞典]]。2010年，在許多歐洲國家/地區將其定為違法，2010年12月，[[歐盟|歐盟]]裁定該法為違法。在[[澳大利亞|澳大利亞]]、[[新西蘭|新西蘭]]和[[美國|美國]]，它被認為是其他非法藥物的類似物，可以通過類似於《聯邦模擬法》的法律加以控制。自2011年10月起，美國於2011年9月將甲氧麻黃酮暫時歸類為非法。

===甲基安非他命===
{{Main|甲基安非他命}}

甲基苯丙胺是一種有效的[[苯乙胺|苯乙胺]]和[[苯丙胺|苯丙胺]]類興奮劑，用於治療[[注意力不足過動症|注意力不足過動症]]（ADHD）和[[肥胖症|肥胖症]]。<ref name = "Malenka">{{cite book|vauthors=Malenka RC, Nestler EJ, Hyman SE |veditors=Sydor A, Brown RY |title=Molecular Neuropharmacology: A Foundation for Clinical Neuroscience |year=2009 |publisher=McGraw-Hill Medical |location=New York |isbn=9780071481274 |page=370 |edition=2nd |chapter=15 |quote=Unlike cocaine and amphetamine, methamphetamine is directly toxic to midbrain dopamine neurons.}}</ref><ref name="Desoxyn">{{cite web |title=Desoxyn Prescribing Information |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/005378s028lbl.pdf |date=December 2013 |work=United States Food and Drug Administration |accessdate=6 January 2014 |archiveurl=https://web.archive.org/web/20140102192621/http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/005378s028lbl.pdf |archivedate=2014-01-02 |dead-url=no }}</ref><ref name="pmid19328213">{{cite journal|vauthors=Krasnova IN, Cadet JL |title=Methamphetamine toxicity and messengers of death |journal=Brain Res. Rev. |volume=60 |issue=2 |pages=379–407 |date=May 2009 |pmid=19328213 |pmc=2731235 |doi=10.1016/j.brainresrev.2009.03.002 |quote=Neuroimaging studies have revealed that METH can indeed cause neurodegenerative changes in the brains of human addicts (Aron and Paulus, 2007; Chang et al., 2007). These abnormalities include persistent decreases in the levels of dopamine transporters (DAT) in the orbitofrontal cortex, dorsolateral prefrontal cortex, and the caudate-putamen (McCann et al., 1998, 2008; Sekine et al., 2003; Volkow et al., 2001a, 2001c). The density of serotonin transporters (5-HTT) is also decreased in the midbrain, caudate, putamen, hypothalamus, thalamus, the orbitofrontal, temporal, and cingulate cortices of METH-dependent individuals (Sekine et al., 2006) ...<br>Neuropsychological studies have detected deficits in attention, working memory, and decision-making in chronic METH addicts ...<br> There is compelling evidence that the negative neuropsychiatric consequences of METH abuse are due, at least in part, to drug-induced neuropathological changes in the brains of these METH-exposed individuals ...<br> Structural magnetic resonance imaging (MRI) studies in METH addicts have revealed substantial morphological changes in their brains. These include loss of gray matter in the cingulate, limbic, and paralimbic cortices, significant shrinkage of hippocampi, and hypertrophy of white matter (Thompson et al., 2004). In addition, the brains of METH abusers show evidence of hyperintensities in white matter (Bae et al., 2006; Ernst et al., 2000), decreases in the neuronal marker, N-acetylaspartate (Ernst et al., 2000; Sung et al., 2007), reductions in a marker of metabolic integrity, creatine (Sekine et al., 2002) and increases in a marker of glial activation, myoinositol (Chang et al., 2002; Ernst et al., 2000; Sung et al., 2007; Yen et al., 1994). Elevated choline levels, which are indicative of increased cellular membrane synthesis and turnover are also evident in the frontal gray matter of METH abusers (Ernst et al., 2000; Salo et al., 2007; Taylor et al., 2007).}}</ref>甲基苯丙胺以[[右旋|右旋]]和[[左旋|左旋]]兩種[[對映體|對映體]]形式存在。<ref name="Kuczenski">{{cite journal|vauthors=Kuczenski R, Segal DS, Cho AK, Melega W |title=Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine |url=https://archive.org/details/sim_journal-of-neuroscience_1995-02_15_2/page/1308 |journal=J. Neurosci. |volume=15 |issue=2 |pages=1308–1317 |date=February 1995 |pmid=7869099 |doi=10.1523/JNEUROSCI.15-02-01308.1995|pmc=6577819 }}</ref><ref name="Mendelson">{{cite journal|vauthors=Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P, Everhart ET, Jones RT |title=Human pharmacology of the methamphetamine stereoisomers |url=https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2006-10_80_4/page/403 |journal=Clin. Pharmacol. Ther. |volume=80 |issue=4 |pages=403–420 |date=October 2006 |pmid=17015058 |doi=10.1016/j.clpt.2006.06.013}}</ref>與[[左旋甲基苯丙胺|左旋甲基苯丙胺]]相比，[[右旋甲基苯丙胺|右旋甲基苯丙胺]]是一種更強的[[中樞神經系統|中樞神經系統]]興奮劑；<ref name="Westfall" /><ref name="Kuczenski" /><ref name="Mendelson" />然而，它們都具有成癮性，並且在高劑量時會產生相同的毒性症狀。<ref name="Mendelson" />儘管由於潛在的風險很少開處方，但鹽酸甲基苯丙胺已被美國食品和藥物管理局（USFDA）批准，商品名為Desoxyn。<ref name="Desoxyn" /> 甲基苯丙胺在娛樂上被用來增加性慾，提升心情和增加精力，使一些使用者連續幾天連續進行性活動。<ref name="Desoxyn" /><ref name="SF Meth" />

甲基苯丙胺可能以純右旋甲基苯丙胺或左右手分子等比例混合的混合物（即50％左旋甲基苯丙胺和50％右旋甲基苯丙胺）非法出售。<ref name="SF Meth">{{cite episode |date=11 August 2013 |title=San Francisco Meth Zombies |url=http://channel.nationalgeographic.com/drugs-inc/episodes/san-francisco-meth-zombies/ |series=Drugs, Inc. |series-link=Drugs, Inc. |season=4 |number=1 |network=National Geographic Channel |minutes=43 |asin=B00EHAOBAO |archiveurl=https://web.archive.org/web/20160708142916/http://channel.nationalgeographic.com/drugs-inc/episodes/san-francisco-meth-zombies/ |archivedate=2016-07-08 |access-date=2020-11-07 |dead-url=no }}</ref>在美國，右甲基苯丙胺和外消旋甲基苯丙胺均為附表II管制物質。<ref name="Desoxyn" />此外，由於甲基苯丙胺已列入《聯合國精神藥物公約》附表二，因此在許多其他國家受到限制或非法生產、分發、銷售和擁有甲基苯丙胺。<ref>{{cite book |author=United Nations Office on Drugs and Crime |title=Preventing Amphetamine-type Stimulant Use Among Young People: A Policy and Programming Guide |publisher=United Nations |location=New York |year=2007 |isbn=9789211482232 |url=http://www.unodc.org/pdf/youthnet/ATS.pdf |accessdate=11 November 2013 |archiveurl=https://web.archive.org/web/20131016082310/http://www.unodc.org/pdf/youthnet/ATS.pdf |archivedate=2013-10-16 |dead-url=no }}</ref><ref name="incb">{{cite web |title=List of psychotropic substances under international control |work=International Narcotics Control Board |publisher=United Nations |url=http://www.incb.org/pdf/e/list/green.pdf |accessdate=19 November 2005 |archiveurl=https://web.archive.org/web/20050907150136/http://www.incb.org/pdf/e/list/green.pdf |archivedate=2005-09-07 |date=August 2003 |dead-url=no }}</ref>相比之下，左旋苯丙胺是美國的一種非處方藥。{{NoteTag|The active ingredient in some OTC inhalers in the United States is listed as ''levmetamfetamine'', the [[International_Nonproprietary_Name|INN]] and [[United_States_Adopted_Name|USAN]] of levomethamphetamine.<ref name="FDA levmetamfetamine">{{cite web|title=CFR TITLE 21: DRUGS FOR HUMAN USE: PART 341 – COLD, COUGH, ALLERGY, BRONCHODILATOR, AND ANTIASTHMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE|url=https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=341.80|website=United States Food and Drug Administration|accessdate=7 March 2016|date=April 2015|quote=Topical nasal decongestants --(i) For products containing levmetamfetamine identified in 341.20(b)(1) when used in an inhalant dosage form. The product delivers in each 800 milliliters of air 0.04 to 0.150 milligrams of levmetamfetamine.|archiveurl=https://web.archive.org/web/20150918190451/http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=341.80|archivedate=2015-09-18|dead-url=no}}</ref><ref>{{cite encyclopedia | title=Levomethamphetamine | section=Identification | section-url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=36604#section=Identification | work=Pubchem Compound | publisher=National Center for Biotechnology Information | access-date=2020-11-07 | archive-date=2014-10-06 | archive-url=https://web.archive.org/web/20141006215922/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=36604#section=Identification | dead-url=no }}</ref>}}

在低劑量下，甲基苯丙胺會引起疲勞的人情緒升高、提高機敏性、注意力和精力。<ref name="Westfall" /><ref name="Desoxyn" />大劑量服用可誘發[[精神病|精神病]]、[[橫紋肌溶解|橫紋肌溶解]]和[[腦出血|腦出血]]。<ref name="Westfall" /><ref name="Desoxyn" /> 已知甲基苯丙胺具有很高的濫用和成癮潛力。<ref name="Westfall" /><ref name="Desoxyn" />娛樂性使用甲基苯丙胺可能會導致精神病或戒斷後綜合症，這種戒斷綜合症可以持續超過典型戒斷期數月。<ref name="Cruickshank-2009">{{cite journal|vauthors=Cruickshank CC, Dyer KR |title=A review of the clinical pharmacology of methamphetamine |url=https://archive.org/details/sim_british-journal-of-addiction_2009-07_104_7/page/1085 |journal=Addiction |volume=104 |issue=7 |pages=1085–1099 |date=July 2009 |pmid=19426289 |doi=10.1111/j.1360-0443.2009.02564.x}}</ref>與[[苯丙胺|苯丙胺]]和[[可卡因|可卡因]]不同，甲基苯丙胺對人類具有[[神經毒性|神經毒性]]，會破壞[[中樞神經系統|中樞神經系統]]（CNS）的[[多巴胺|多巴胺]]和[[5-羥色胺|5-羥色胺]]神經元。<ref name = "Malenka" /><ref name="pmid19328213" />與長期使用苯丙胺完全相反的是，有證據表明，甲基苯丙胺會因長期使用而對人造成大腦損害； <ref name = "Malenka" /><ref name="pmid19328213" />這種損害包括大腦結構和功能的不利變化，例如減少灰質。 腦幾個區域的血容量和代謝完整性標誌物的不利變化。<ref name="Neuroplasticity 1">{{cite journal|vauthors=Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K |title=Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects |journal=JAMA Psychiatry |volume=70 |issue=2 |pages=185–198 |date=February 2013 |pmid=23247506 |doi=10.1001/jamapsychiatry.2013.277 |url=}}</ref><ref name="Neuroplasticity 2">{{cite journal|vauthors=Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J |title=Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies |journal=J. Clin. Psychiatry |volume=74 |issue=9 |pages=902–917 |date=September 2013 |pmid=24107764 |doi=10.4088/JCP.12r08287 |url=https://archive.org/details/sim_journal-of-clinical-psychiatry_2013-09_74_9/page/902|pmc=3801446}}</ref><ref name="pmid19328213" />

===派醋甲酯=== 
{{Main|派醋甲酯}}
派醋甲酯是一種中樞神經系統興奮劑 其結構和藥理與安非他命、古柯鹼相似,能改善使用者的情緒和專注力，被應用於注意力不足過動症（ADHD）、嗜睡症、躁鬱症和憂鬱症的治療。

===古柯鹼===
[[File:Cocaine_lines_2.jpg|thumb]]
{{Main|古柯鹼}}
可卡因是一種[[5-羥色胺、去甲腎上腺素和多巴胺再攝取抑制劑|5-羥色胺、去甲腎上腺素和多巴胺再攝取抑制劑]]，可卡因由[[古柯|古柯]]灌木的葉子製成，古柯灌木生長在[[南美|南美]]國家的[[玻利維亞|玻利維亞]]、[[哥倫比亞|哥倫比亞]]和[[秘魯|秘魯]]等山區。在[[歐洲|歐洲]]、[[北美|北美]]和[[亞洲|亞洲]]的某些地區，可卡因最常見的形式是白色結晶性粉末。可卡因是一種興奮劑，儘管可卡因將臨床用途視為局部麻醉劑，特別是在[[眼科|眼科]]領域，但由於其興奮性而通常在治療上並未開處方。可卡因的大多數使用是[[娛樂性用藥|娛樂性]]的，其[[藥物濫用|濫用]]潛力很高（高於[[苯丙胺|苯丙胺]]），因此在大多數轄區都嚴格控制其銷售和擁有。其他與可卡因有關的[[莨菪烷|莨菪烷]]衍生物藥物也眾所周知，例如troparil和lometopane，但尚未廣泛銷售或用於娛樂。<ref>{{cite journal|author1=AJ Giannini |author2=WC Price |title=Contemporary drugs of abuse |url=https://archive.org/details/sim_american-family-physician_1986-03_33_3/page/207 |journal=American Family Physician |volume=33 |pages=207–213 |year=1986}}</ref>

===尼古丁===
{{Main|尼古丁}}
尼古丁是[[煙草|煙草]]中的活性化學成分，有多種形式，包括[[香煙|香煙]]、[[雪茄|雪茄]]、咀嚼煙草和戒菸輔助劑，例如[[尼古丁貼片|尼古丁貼片]]、[[尼古丁口香糖|尼古丁口香糖]]和[[電子香煙|電子香煙]]。尼古丁具有刺激和放鬆作用，因此在世界範圍內得到廣泛使用。尼古丁通過[[菸鹼乙酰膽鹼受體|菸鹼乙酰膽鹼受體]]的激動作用發揮其作用，從而導致多種下游效應，例如中腦[[獎賞系統|獎賞系統]]中[[多巴胺能|多巴胺能]]神經元活性的增加，其中一種菸葉乙醛降低了大腦中[[單胺氧化酶|單胺氧化酶]]的表達。<ref>{{cite journal|last1=Talhouth|first1=Reinskje|last2=Opperhuizen|first2=Antoon|last3=van Amsterdam G. C.|first3=Jan|title=Role of acetaldehyde in tobacco smoke addiction|journal=European Neuropsychopharmacology|date=October 2007|volume=17|issue=10|pages=627–636|doi=10.1016/j.euroneuro.2007.02.013|pmid=17382522}}</ref>尼古丁會[[上癮|上癮]]並形成依賴性。煙草是尼古丁最常見的來源，對使用者和自己的總體危害比可卡因低3％，比苯丙胺高13％，在通過多標準決策分析確定的20種藥物中，危害最大的是第六位。<ref>{{cite journal|last1=Nutt|first1=David J.|last2=King|first2=Leslie A.|last3=Phillips|first3=Lawrence D.|title=Drug harms in the UK: a multicriteria decision analysis|journal=Lancet |date=6 November 2010|volume=376|issue=9752|pages=1558–1565|doi=10.1016/S0140-6736(10)61462-6|pmid=21036393|issn=1474-547X}}</ref>

== 醫療用途 ==
中樞神經刺激劑在醫學上用來治療[[肥胖|肥胖]]、[[睡眠疾患|睡眠疾患]]、[[narcolepsy|嗜睡症]]（narcolepsy）、[[情感性疾患|情感性疾患]]、[[注意力不足過動症|注意力不足過動症]]、{{tsl|en|treatment-resistant depression|頑固型憂鬱症}}、{{tsl|en|treatment-resistant obsessive compulsive disorder|頑固型強迫症}}、[[氣喘|氣喘]]、和[[鼻塞|鼻塞]]等。
<ref name="NIMH on stimulant"/>
<ref>
{{cite journal
|last1=Harper
|first1=S. J.
|last2=Jones
|first2=N. S.
|title=Cocaine: what role does it have in current ENT practice? A review of the current literature
|journal=The Journal of Laryngology and Otology
|date=1 October 2006
|volume=120
|issue=10
|pages=808–811
|doi=10.1017/S0022215106001459
|pmid=16848922
|issn=1748-5460}}</ref>  

===注意力不足過動症===
用來治療ADHD的興奮劑包含：
* [[哌甲酯|哌甲酯]]
* [[苯丙胺|苯丙胺]]
* [[右旋安非他命|右旋安非他命]] 
* {{tsl|en|Lisdexamfetamine Dimesylate}}
<ref name="NIMH on stimulant"/>

==安全性==
只要按照指示使用，中樞神經刺激劑如同其他藥品一樣安全，不會導致[[藥物濫用|藥物濫用]]或[[成癮|成癮]]。研究顯示，以中樞神經興奮劑治療注意力不足過動症的患者，其往後將比<u>沒有</u>以中樞神經興奮劑治療的注意力不足過動症患者享有明顯更低的藥物濫用風險。<ref name="NIMH on stimulant"/>

==副作用==
如同其他藥物，中樞神經刺激劑也有副作用產生的可能，然而不是每個服用興奮劑的人都會有副作用。中樞神經刺激劑的副作用大都輕微（minor）並且在劑量降低或與其他藥物併用、調整服藥時間等調適後消失。

較常見的副作用{{NoteTag|name=adverse effect|1=「常見副作用」的定義為：在臨床試驗中，實驗組中至少5
%的人出現此症狀，且在實驗組中出現此反應的比例為安慰組的兩倍。}}包含：<!--The most common side effects include:-->
* 難以入睡或難以維持睡眠。
* 胃口降低。
* 胃部不適。
* 頭疼。
較少見的副作用{{NoteTag|name=less common side effects|1=「較少見的副作用」的定義為：在臨床試驗中，實驗組中至少2
%的人出現此症狀，且在實驗組中出現此反應的比例多於安慰組。}}包含：
* 肢體抽動或聲音抽動。（突然的、重複的動作或聲音）(抽搐)
<ref name="NIMH on stimulant"/>

==備註==
{{NoteFoot}}

== 参考文献 ==
{{Reflist|33em}}

== 参见 ==
{{Portal|药理学|医学|体育运动}}
*[[抗精神病药|抗精神病药]]
*{{le|Depressant|Depressant}}
*[[致幻剂|致幻剂]]
*[[益智药|益智药]]
*[[抑制劑|抑制劑]]
 
{{-}}
{{主要药物分类}}
{{抗抑鬱藥}}
{{ADHD_pharmacotherapies}}
<!--{{Stimulants}}-->
{{Drug use}}

{{Authority control}}
[[Category:兴奋剂|]]
[[category:药物|category:药物]]
[[category:超人类主义|category:超人类主义]]
[[Category:精神藥理學|Category:精神藥理學]]
[[Category:注意力不足過動症的治療|Category:注意力不足過動症的治療]]